<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

X-MAN™ Isogenic DualXeno™ Models with KRAS Mutation Predicts the Effect of Anti-EGFR Agents

We have previously reported using cell lines generated with Horizon Discovery’s rAAV-based GENESIS™ gene editing platform to establish a comprehensive list of isogenic cancer models for in vivo compound screening, with mutations in a wide variety of genes including KRAS, PIK3CA, PTEN, IDH1 and IDH2, and p53.